Qlife Holding AB (publ)

Stockholm Stock Exchange QLIFE.ST

Qlife Holding AB (publ) Price to Book Ratio (P/B) on January 14, 2025

Qlife Holding AB (publ) Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Qlife Holding AB (publ) 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Qlife Holding AB (publ) 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Qlife Holding AB (publ) average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: QLIFE.ST

Qlife Holding AB (publ)

CEO	Mr. Thomas Warthoe
IPO Date	March 2, 2020
Location	Sweden
Headquarters	Redaregatan 48
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Qlife Holding AB (publ), a med-tech company, manufactures and sells in-vitro diagnostic analyzers and reagents. The company offers Egoo.Health Platform, an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. Its biomarkers include C-reactive protein home-testing capsule, PHE/Phenylalanine for PKU patients, and Sars-CoV-2/Influenza multiplex for virus/bacteria tests. The company was incorporated in 2019 and is based in Helsingborg, Sweden.

Key trends

Past 5 years